Humacyte (HUMA) Falls 11.3% Over 30 Days as Earnings Miss and Nasdaq Notice Weigh on Shares
Key Takeaways
- Humacyte shares fell approximately 11.3% in the 30 days ended August 14, 2026, based on available closing prices of $0.6816 on July 15 and $0.6048 on August 14.
- The decline sharpened after second-quarter results missed consensus revenue and EPS expectations, renewing concerns about SYMVESS commercialization and cash burn.
- A Nasdaq minimum-bid notice and an extended stretch below $1.00 per share added to selling pressure.
- Positive V012 Phase III dialysis-access data and a planned supplemental BLA filing are key clinical catalysts, but they have not offset near-term execution and dilution concerns.
- Over the broader three-month window from May 15 to August 14, the stock fell about 35%.
Humacyte (HUMA) Company Overview and Market Position
Humacyte, Inc. is a commercial-stage biotechnology company developing universally implantable, bioengineered human tissues at commercial scale. Its lead product, SYMVESS, is an acellular tissue engineered vessel approved by the U.S. Food and Drug Administration for use as an arteriovenous graft in adults with extremity vascular trauma when autologous vein grafting is not feasible.
The company's platform targets vascular repair and replacement markets, including hemodialysis access, peripheral artery disease, and coronary artery bypass grafting. Investors follow HUMA for its novel off-the-shelf vessel technology, pipeline optionality, and long-term addressable market in dialysis access, while weighing early-stage commercial execution and funding requirements. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Humacyte (HUMA) Stock Price Performance: Last 30 Days vs. Quarter
Using available closing prices, HUMA's most recent close was $0.6048 on August 14, 2026. Thirty calendar days earlier, on July 15, 2026, shares closed at $0.6816. That represents a decline of approximately 11.3% over the 30-day period.
The 30-day move is part of a longer slide. From May 15, 2026, when shares closed at $0.9301, through August 14, the stock fell roughly 35%. The trend was not a straight line: HUMA rallied into early June before a dilutive offering and, later, a second-quarter earnings miss pushed shares decisively below $1.00.
What Drove HUMA Stock Price in the Last 30 Days
The primary catalyst was second-quarter earnings. On August 12, 2026, Humacyte reported commercial revenue of $0.4 million for the June quarter and a net loss of $36.8 million, or $0.16 per share. Revenue and EPS came in below consensus expectations, and the company recorded an inventory reserve and costs tied to unused production capacity.
Management acknowledged that SYMVESS adoption had been slower than expected and that the company underestimated the education required to introduce a new vascular conduit. The rebuilt commercial organization is targeting at least 20 major U.S. healthcare systems in the second half of 2026, but the update highlighted near-term execution risk.
Separately, Humacyte disclosed a Nasdaq notice on July 31, 2026, after shares closed below $1.00 for 30 consecutive business days. The company has until January 27, 2027, to regain compliance. The sub-$1 trading range, combined with a June 2026 public offering that raised $57.5 million, reinforced concerns about dilution and financing needs.
Clinical news remained a bright spot. Interim V012 Phase III data showed the ATEV delivered 91 more catheter-free days than an autologous arteriovenous fistula in female dialysis patients, with a statistically significant p-value of 0.0007. Humacyte also reported a lower infection rate for the ATEV. Analyst actions reflected the divide: several firms maintained bullish ratings after the V012 update, while at least one independent research service moved to a bearish rating in mid-August. The company plans a supplemental BLA filing for dialysis access in November 2026.
What Drove HUMA Stock Performance Over the Last Quarter
The broader three-month decline reflected a conflict between positive clinical data and pressing capital-markets realities. The period followed first-quarter results that showed Symvess sales growth but a revenue miss and ongoing losses. Shares then rallied into early June on anticipation of the V012 dialysis-access readout.
On June 10, 2026, Humacyte announced positive interim V012 results. However, the company simultaneously priced a public offering of 47.6 million shares at $1.05 per share, and the dilutive raise overwhelmed the positive data. The stock fell sharply and entered a prolonged stretch below $1.00.
Cost-cutting has not reversed sentiment. A workforce restructuring is expected to generate about $14.3 million in net savings in 2026, and the company held $80.3 million in cash, cash equivalents, and restricted cash as of June 30, 2026. Yet the market has continued to focus on slow Symvess uptake, the Nasdaq compliance clock, and the likelihood of additional capital needs before a potential dialysis approval. From what I see, the tension between clinical progress and balance-sheet pressures remains the central theme.
HUMA Stock Forecast Drivers: What Investors Should Watch Next
The next major catalyst is the planned supplemental BLA filing for the ATEV in dialysis access, targeted for November 2026. Humacyte intends to request priority review; if granted, management has pointed to a potential PDUFA date around May 2027. A standard review timeline could extend that timeline into August 2027.
Commercial execution will be equally important. Investors are likely to monitor SYMVESS hospital adoptions, the number of accounts moving through value analysis committees, and any sequential revenue acceleration. The coronary tissue engineered vessel program is also advancing, with a Phase IIa study expected to begin in the third quarter of 2026.
Key risks include the Nasdaq listing compliance deadline of January 27, 2027, ongoing cash burn, potential future dilution, and the execution challenges of launching a first-in-class surgical product. Regulatory decisions, reimbursement developments, and broader biotechnology sentiment may also influence trading. I’m watching this closely as the November filing approaches.
Using Tickeron AI Tools in My Analysis
In my research process, I regularly consult Tickeron’s AI tools to cross-check patterns and compare performance metrics across similar names. For volatile biotech stocks like HUMA, these resources provide an additional data layer that complements fundamental work without replacing independent judgment. The AI Daily Buy/Sell Signals and related platforms help highlight how algorithmic models are responding to the same catalysts I’m tracking.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
HUMA's RSI Oscillator recovers from oversold territory
The RSI Indicator for HUMA moved out of oversold territory on August 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 35 of the 39 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 57 cases where HUMA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for HUMA just turned positive on September 18, 2026. Looking at past instances where HUMA's MACD turned positive, the stock continued to rise in 30 of 38 cases over the following month. The odds of a continued upward trend are 79%.
Following a +2.59% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUMA advanced for three days, in 195 of 238 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUMA as a result. In 80 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.203) is normal, around the industry mean (25.951). P/E Ratio (1.024) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (52.083) is also within normal values, averaging (436.793).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. HUMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement